HPMA copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer

Advances in Experimental Medicine and Biology

Volumn 519, Issue , 2003, Pages 101-123

  Peterson, C Matthew ^a   Shiah, Jane Guo ^a   Sun, Yongen ^a   Kopečková, Pavla ^a   Minko, Tamara ^a   Straight, Richard C ^a   Kopeček, Jindrich ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; ETHYLENEDIAMINE; GALACTOSAMINE; HEMATOPORPHYRIN DERIVATIVE; MACROGOL; MESOCHLORIN E6; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PACLITAXEL; PHOTOFRIN II; PHOTOSENSITIZING AGENT; PLATINUM DERIVATIVE; POLYGLUTAMIC ACID; TETRAPEPTIDE; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BIODEGRADABILITY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG RETENTION; FEBRILE NEUTROPENIA; HUMAN; IMMUNOGENICITY; MUCOSA INFLAMMATION; NONHUMAN; OVARY CANCER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CLINICAL TRIALS; DOXORUBICIN; EXCIPIENTS; FEMALE; HUMANS; METHACRYLATES; OVARIAN NEOPLASMS; PHOTOCHEMOTHERAPY; SUBCELLULAR FRACTIONS; TISSUE DISTRIBUTION;

EID: 0037957200     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (58)

1. Oriel KA, Hartenbach EM, Remington PL. Trends in United States ovarian cancer mortality: 1979-1995. Obstet Gynecol 93:30-33 (1999).
2. NIH Consensus Development Panel. Ovarian cancer: Screening, treatment, and follow-up. JAMA 273:491-497 (1995).
3. Wolff BE, Sugarbaker RH. Intraperitoneal chemotherapy and immunotherapy. Recent Res Cancer Res 110:254-273 (1988).
4. Brenner DE. Intraperitoneal chemotherapy: A review. J Clin Oncol 4:1135-1147 (1986).
5. Yong RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 250:3072 (1983).
6. Berek J. Epithelial ovarian cancer. In: Practical Gynecological Oncology, Berek JS, Hacker NS (eds), Williams and Wilkins, Philadelphia, PA, 366 (1994).
7. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. Br Med J 9:89 (1991).
8. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and ciplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 9:1668 (1991).
9. Williams CJ. Implications of an Overview of Chemotherapy in Advanced Ovarian Carcinoma. Br J Cancer 66:225-6 (1992)
10. Putnam D, Kopecek J. Polymer conjugates with anticancer activity. Adv Polym Sci 122:55-123 (1995).
11. Reynolds T. Polymers Help Guide Cancer Drugs to Tumor Targets- Keep Them There. J Natl Cancer Inst 87:1582 (1995).
12. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherpay: mechanisms of tumoritropic accumulation of proteins and antitumor agent SMANCS. Cancer Res 6:6387 (1986).
13. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307-14 (1998).
14. 6 and adriamycin in nude Mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Contr Rel 61:145-57 (1999)
15. Seymour LW, Ulbrich K, Strohalm J, Kopeček J. The pharmacokinetics of polymerbound adriamycin, Biochem Pharmacol 39:1125-30 (1990)
16. Remanová P, Kopeček J, Duncan R, Lloyd JB. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide) copolymers. Biomaterials 6:45-48 (1985).
17. Simekova J, Plocova, Řihová B, Kopeček J. Activation of complement in the presence of in N-(2-hydroxypropyl)methacrylamide) copolymers. J Bioact Comp Polym 1:20-31 (1986).
18. Lloyd JB, Duncan R, Kopeček J. Synthetic polymers as targetable carriers for drugs. Pure Appl Chem 56:1301-1304 (1984).
19. Kopeček J. Controlled degradability of polymers-a key to drug delivery systems. Biomaterials 5:19-25 (1984).
20. Omelyanenko V, Kopečeková P, Gentry C, Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Rel 53:25-37 (1998).
21. Slobbe R, Poels L, tenDam G, Boerman O, Nieland L, Leunissen J, Ramaekers F, VanEys G. Analysis of idiotype structure of ovarian cancer antibodies: Recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences. Clin Exp Immunot 98:95-103 (1994).
22. Li S, Deshrnukh HM, Huang L Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm Res 15:1540-1545 (1998).
23. Maeda H, Seymour LM, Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug Chem 3:351-362 (1992).
24. Duncan R. Drug-polymer conjugates:potential for improved chemotherapy. Anticancer Drugs 3:175-210 (1992).
25. Řihova R, Kopeček J, Ulbrich K, Chytry V. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers. Makromol Chem Suppl 9:13-24 (1985).
26. Cuvier C, Robot-Treupel L, Millot JM, Lizard G, Chevillard S, Manfait M, Couvreur P, Poupon MF. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharm 44:509-517 (1992).
27. Bodley AL, Liu LF. Topoisomerase as novel targets for cancer chemotherapy. Biotechnology 6:1315-1319 (1988).
28. Denny WA. DNA-intercalating ligands as anticancer drugs: prospects for future design. Anti-Cancer Drug Des 4:241-249 (1989).
29. Bristow MR, Billingham ME, Masson JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873-878 (1978).
30. Lefrak EA, Pitha J, Rosenheim S, O'Bryan RM, Burgess MA, Gottlieb JA. Adriamycin (NSC 123127) cardiomyopathy. Cancer Chemother Rep 6:203-208 (1975).
31. Ogura R, Sugiyama M, Haramaki N, Hidaka T. Electron spin resonance studies on the mechanism of Adriamycin-induced heart mitochondrial damages. CancerRes 51:3555-3558 (1991).
32. Lu JM, Peterson CM Sun Y, Peterson CA, Shiah J-G, Straight RC, Kopeček J. Cooperativity between free and N-(2-hydroxypropyl)methacrylamide copolymer bound adriamycin and mesochlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro. Int J Oncol 15:5-16 (1999).
33. Peterson CM, Lu JM, Sun Y, Peterson CA, Shiah JG, Straight RC, Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Clin Cancer Res 56:83-94 (1999).
34. Duncan R, Kopečeková P, Strohalm J, Hume IC, Lloyd JB, Kopeček J. Anticancer agents coupled to N-(2-hydroxyprophyl)methacrylamide copolymers 2. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Brit J Cancer 57:147-156 (1988).
35. Vasey P, Twelves C, Kaye S, Wilson P, Morrison R, Duncan R, Thomson A, Hilditch T, Murray T, Burtles S, Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents: drug-polymer conjugates. Clin Cancer Res 5:83-94 (1999).
36. Minko T, Kopečeková P, Kopeček J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm Res 16:986-996 (1999).
37. Seymour LW, Duncan R, Strohalm J, Kopeček J. Effect of molecular weight (Mw) of of N-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J J Biomed Mater Res 21:1341-58 (1987).
38. Řihová B, Ulbrich K, Kopeček J, Mančal P. The immunogenicty of N-(2-hydroxypropyl) methacrylamide copolymers-potential hapten or drug carriers. Folia Microbiol 28:217-27 (1983).
39. Řihová B, Kopeček J, Ulbrich K, Pospišil M, Mančal P. Effect of the chemical structure of N-(2-hydroxypropyl) methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 5:143-8 (1984).
40. Řhová B, Kopeček J, Ulbrich K, Chytry V. Immunogenicity of N-(2-hydroxypropyl) methacrylamide copolymers. Makromol. Chem Supl 9:13-24 (1995).
41. Simeckova J, Řihová B, Plocová D, Kopeček J. Activity of complement in the presence of N-(2-hydroxypropyl) methacrylamide copolymers. J Bioact Compat Polymers 1:20-31 (1986).
42. Řhová B, Bilej M, Větvička V. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing doxorubicin. Biomaterials. 10:335-42 (1989).
43. Vasey PA, Duncan R, Kaye SB, Cassidy J. Phase 1 clinical and pharmacokinetic study of PK1 (N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug polymer conjugates. EROTC Abstract
44. Duncan R, Seymour LW, O'Hare KB, Flanagan PA, Wedge S, Ulbrich K, Strohalm J, Subr V, Spreafico F, Grandi M, Ripamonti M, Farao M, Suarato A. Preclinical evaluation of polymer bound doxorubicin. J Controlled Rel 19:331-46 (1992).
45. Thomson AH, Vasey PA, Murray LS, Cassidy J, Fraier D, Frigerio E, Twleves C. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumors. Br J Ca 81:99-107 (1999).
46. Loadman PM, Bibby MC, Double JA, Al-Shakhaa WM, Duncan R. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin Cancer Res 5:3682-8 (1999)
47. Peterson CM, Reed R, Jolles CJ, Jones KP, Straight RC, Poulson AM. Photodynamic therapy of human ovarina epithelial carcinoma, OVCAR-3, heterotransplanted in the nude mouse. Am J Obstet Gynecol 167:1852-5 (1992).
48. Chaplin DJ. The effect of photodynamic therapy on tumor vascular function. Int J Radiat Biol 60:311-325 (1991).
49. Feyh J, Goetz A, Heiman A, Konigsberger R, Kastenbauer E. Microcirculatory effects of photodynamic therapy with hematoporphyrin derivative. Laryngo-Rhino-Otol 70:99-101 (1991).
50. Moan J. Porphyrin-sensitized photodynamic inactivation of cells: A review. Lasers Med Sci 1:5-12 (1986).
51. Kennedy JC, Nadeau P, Petryka ZJ, Pottier RH, Weagle G. Clearance times of photophyrin derivatives from mice as measured by in vivo fluorescence spectroscopy. Photochem Photobiol 55:729-734 (1992).
52. Shiah J-G, Koňák Č, Spikes JD, Kopeček J. Influence of pH on aggregation and photoproperties of N-(2-hydroxypropyl)methacrylamide copolymer-meso chlorin e6 conjugates. Drug Delivery 5:119-26 (1998)
53. Brophy PF, Keller SM. Adriamycin enhanced in vitro and in vivo photodynamic therapy of mesothelioma. J Surg Res 52:631-634 (1992).
54. 6 monoethylene diaamine in human ovarian carcinoma (OVCAR-3) in vivo. J Soc Gynecol Invest 2:772-777 (1995).
55. 6 and adriamycin in combination treatments. Clin Cancer Res 6:1008-15 (2000).
56. Krinick NL, Sun Y, Joyner D, Spikes JD, Straight RC, Kopeček J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J Biomat Sci, Polym Ed 5:303-324 (1994).
57. Minko T, Kopečekova, Kopeček J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer 86:108-17 (2000).
58. Minko T, Kopečeková P, Pozharov V, Jensen KD, Kopeček J. The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability and retention effect in resistant solid tumor. Pharm Res 17:505-14 (2000).